BryoLogyx Announces Additions to Board of Directors and Scientific and Medical Advisory Board
(Photo credit: BryoLogyx, Inc.) DANVILLE, CA (October 13)—BryoLogyx, Inc. announced today that it has chemically-synthesized the bryostatin-1 molecule (above) under FDA’s Good Manufacturing Practice (GMP) regulations. Its manufacture is in preparation for clinical trials to study its potential to improve the response to cancer immunotherapies and additional preclinical research. The molecule was originally sourced from a marine invertebrate organism by the NCI. Bryostatin-1 is a potent, highly complex macrolide that had proved nearly intractable to chemically synthesize. The manufacture was based on a fully synthetic process developed at Stanford University by Dr. Paul Wender and colleagues www.bryologyx.com.
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), to conduct a Phase I clinical trial with bryostatin-1 in pediatric and young adult patients with relapsing or refractory CD22 expressing acute lymphoblastic leukemia (ALL) and lymphoma. The study, expected to start later this year, will be the first in patients to evaluate the ability of bryostatin-1 to upregulate expression of CD22, a cancer immunotherapy target often downregulated following antibody drug conjugate or CAR T adoptive therapies. The Company is planning future clinical trials with bryostatin-1 to evaluate its ability to upregulate other antigen targets associated with B cell hematological malignancies.
BryoLogyx Inc. has entered into two agreements with Neurotrope, Inc. to acquire Neurotrope’s preclinical data and drug product bryostatin-1 for an immuno-oncology application, and to supply Neurotrope with synthetic bryostatin-1 for clinical trials and commercialization for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Financial terms were not disclosed.